The θ-defensin retrocyclin 101 inhibits TLR4- and TLR2-dependent signaling and protects mice against influenza infection
- 1 October 2017
- journal article
- Published by Oxford University Press (OUP) in Journal of Leukocyte Biology
- Vol. 102 (4) , 1103-1113
Abstract
Despite widespread use of annual influenza vaccines, seasonal influenza-associated deaths number in the thousands each year, in part because of exacerbating bacterial superinfections. Therefore, discovering additional therapeutic options would be a valuable aid to public health. Recently, TLR4 inhibition has emerged as a possible mechanism for protection against influenza-associated lethality and acute lung injury. Based on recent data showing that rhesus macaque θ-defensins could inhibit TLR4-dependent gene expression, we tested the hypothesis that a novel θ-defensin, retrocyclin (RC)-101, could disrupt TLR4-dependent signaling and protect against viral infection. In this study, RC-101, a variant of the humanized θ-defensin RC-1, blocked TLR4-mediated gene expression in mouse and human macrophages in response to LPS, targeting both MyD88- and TRIF-dependent pathways. In a cell-free assay, RC-101 neutralized the biologic activity of LPS at doses ranging from 0.5 to 50 EU/ml, consistent with data showing that RC-101 binds biotinylated LPS. The action of RC-101 was not limited to the TLR4 pathway because RC-101 treatment of macrophages also inhibited gene expression in response to a TLR2 agonist, Pam3CSK4, but failed to bind that biotinylated agonist. Mouse macrophages infected in vitro with mouse-adapted A/PR/8/34 influenza A virus (PR8) also produced lower levels of proinflammatory cytokine gene products in a TLR4-independent fashion when treated with RC-101. Finally, RC-101 decreased both the lethality and clinical severity associated with PR8 infection in mice. Cumulatively, our data demonstrate that RC-101 exhibits therapeutic potential for the mitigation of influenza-related morbidity and mortality, potentially acting through TLR-dependent and TLR-independent mechanisms.Keywords
Funding Information
- U.S. National Institutes of Health (AI-18797, AI-125215, NS-066842, AI-072732)
- National Institute of Allergy and Infectious Diseases
- National Institute of Neurological Disorders and Stroke
This publication has 75 references indexed in Scilit:
- The TLR4 antagonist Eritoran protects mice from lethal influenza infectionNature, 2013
- Potential role for alternatively activated macrophages in the secondary bacterial infection during recovery from influenzaImmunology Letters, 2012
- Human β‐defensin 3 affects the activity of pro‐inflammatory pathways associated with MyD88 and TRIFEuropean Journal of Immunology, 2011
- MyD88 Signaling Is Indispensable for Primary Influenza A Virus Infection but Dispensable for Secondary InfectionJournal of Virology, 2010
- A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine releaseProceedings of the National Academy of Sciences, 2010
- Human β‐defensin 3 has immunosuppressive activity in vitro and in vivoEuropean Journal of Immunology, 2010
- Novel signaling interactions between proteinase-activated receptor 2 and Toll-like receptors in vitro and in vivoMucosal Immunology, 2009
- Predominant Role of Bacterial Pneumonia as a Cause of Death in Pandemic Influenza: Implications for Pandemic Influenza PreparednessThe Journal of Infectious Diseases, 2008
- Analyzing real-time PCR data by the comparative CT methodNature Protocols, 2008
- RIG-I-Mediated Antiviral Responses to Single-Stranded RNA Bearing 5'-PhosphatesScience, 2006